Intranasal steroid reduces exhaled bronchial cysteinyl leukotrienes in allergic patients.
BACKGROUND
Allergic rhinitis (AR) precedes and is often associated with bronchial asthma. Indeed, local and systemic inflammations in both conditions are very similar. Cysteinyl-leukotrienes (cys-LTs) are generated during early- and late-phase allergic reactions and induce smooth-muscle contraction, microvascular leakage, and mucous hypersecretion. Cys-LTs are detected in exhaled breath condensate (EBC) of asthmatics and regardless of bronchial symptoms, they are also found in EBC of rhinitic patients.


OBJECTIVE
To evaluate cys-LTs in EBC of allergic patients and to assess the activity of nasal fluticasone propionate (FP) on EBC cys-LTs levels.


METHODS
Cys-LTs coefficient of variation (CV) was evaluated from different EBC in 5 healthy volunteers. Cys-LTs levels from EBCs in 13 healthy controls and 56 allergic rhinitic (n=31) and rhinitic/asthmatic (n=25) patients were also evaluated at baseline. Subsequently patients were randomized to receive either FP 100 microg/day per nostril or placebo for 2 weeks and then re-evaluated for EBC cys-LTs.


RESULTS
The CV was 14.12%. EBC cys-LTs in allergic patients were significantly higher than in healthy subjects (70.9 vs. 20.6 pg/mL (median), P<0.05), while it did not differ between asthmatic/rhinitic and purely rhinitic patients. Treatment significantly reduced cys-LTs (from 93.6 to 19.9 pg/mL, P<0.001). This effect was evident both in asthmatic/rhinitic and in rhinitic patients.


CONCLUSIONS
Treatment of AR with FP significantly reduces the levels of cys-LTs, major noninvasive markers of lower airway inflammation, suggesting that upper and lower airway inflammation is present and should be thus treated as a whole in subjects with AR with and without asthma.
Failla
M
M
Department of Internal and Specialistic Medicine, Section of Respiratory Medicine, University of Catania, Catania, Italy.
Biondi
G
G
Provvidenza Pistorio
M
M
Gili
E
E
Mastruzzo
C
C
Vancheri
C
C
Crimi
N
N
D000281:Administration, Intranasal; D000328:Adult; D000730:Androstadienes / Q000494:pharmacology* / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D015415:Biomarkers / Q000378:metabolism; D001944:Breath Tests / Q000379:methods; D001980:Bronchi / Q000378:metabolism*; D003545:Cysteine / Q000378:metabolism*; D004311:Double-Blind Method; D005260:Female; D000068298:Fluticasone; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D015289:Leukotrienes / Q000378:metabolism*; D008297:Male; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D014797:Vital Capacity / Q000187:drug effects
D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D015289:Leukotrienes; C112381:cysteinyl-leukotriene; D000068298:Fluticasone; D003545:Cysteine